These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

801 related items for PubMed ID: 15050976

  • 1. Developing treatments for inborn errors: incentives available to the clinician.
    Haffner ME.
    Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
    [Abstract] [Full Text] [Related]

  • 2. Therapies for inborn errors of metabolism: what has the orphan drug act delivered?
    Talele SS, Xu K, Pariser AR, Braun MM, Farag-El-Massah S, Phillips MI, Thompson BH, Coté TR.
    Pediatrics; 2010 Jul; 126(1):101-6. PubMed ID: 20566615
    [Abstract] [Full Text] [Related]

  • 3. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [Abstract] [Full Text] [Related]

  • 4. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
    Wellman-Labadie O, Zhou Y.
    Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435
    [Abstract] [Full Text] [Related]

  • 5. [Hope for patients with rare diseases--"orphan" drugs].
    Kuzelová M, Kubácková K, Palágyi M, Smíd M.
    Cas Lek Cesk; 2006 May; 145(4):296-300. PubMed ID: 16639930
    [Abstract] [Full Text] [Related]

  • 6. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC, He L, He G, He Y.
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [Abstract] [Full Text] [Related]

  • 7. What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis.
    Thorat C, Xu K, Freeman SN, Bonnel RA, Joseph F, Phillips MI, Imoisili MA.
    Pediatrics; 2012 Mar; 129(3):516-21. PubMed ID: 22371464
    [Abstract] [Full Text] [Related]

  • 8. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
    Pariser AR, Xu K, Milto J, Coté TR.
    Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Orphan drug development in the United States.
    Groft SC.
    CPJ; 1985 May; 118(5):219-22. PubMed ID: 10271306
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Orphan drug legislation: lessons for neglected tropical diseases.
    Villa S, Compagni A, Reich MR.
    Int J Health Plann Manage; 2009 May; 24(1):27-42. PubMed ID: 18435430
    [Abstract] [Full Text] [Related]

  • 15. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases.
    Xu K, Coté TR.
    Brief Bioinform; 2011 Jul; 12(4):341-5. PubMed ID: 21357612
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.
    Le TT.
    Adv Exp Med Biol; 2017 Jul; 1031():183-196. PubMed ID: 29214572
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Orphan Drug Act on congressional agenda.
    von Oehsen WH.
    Physician Exec; 1989 Jul; 15(3):34-5. PubMed ID: 10313123
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.